BillionToOne (BLLN) Registration Filing summary

Company overview and business model

• Specializes in precision molecular diagnostics using a proprietary single-molecule NGS (smNGS) platform for prenatal and oncology testing.

• Offers category-defining products: UNITY for prenatal screening and Northstar for oncology liquid biopsy, both leveraging high sensitivity and quantification.

• Business model is based on test volume and average selling price (ASP), with revenue primarily from third-party payors.

• Focuses on expanding test menu, automation, and AI integration to drive operational efficiency and product innovation.

Financial performance and metrics

• Revenue grew from $8M in 2021 to $152.6M in 2024, with 113% YoY growth in 2024 and 82% YoY growth in H1 2025.

• Gross margin improved from 24% in 2023 to 53% in 2024, reaching 65% in H1 2025.

• Net loss decreased from $82.7M in 2023 to $41.6M in 2024, and to $4.2M in H1 2025.

• Non-GAAP operating income turned positive in H1 2025 ($1.2M), with EBITDA and adjusted EBITDA also showing improvement.

• As of June 30, 2025, cash and cash equivalents were $188.96M, with $52.1M in long-term debt and an accumulated deficit of $286.4M.

Use of proceeds and capital allocation

• Net proceeds of ~$180.4M (or $208.3M if underwriters' option exercised) to be used for working capital, R&D, technology development, and general corporate purposes.

• May use a portion for acquisitions or investments in complementary products, technologies, or businesses.

• No current plans for dividends; all earnings to be retained for growth and operations.